3-(2-(2,2-diethylhydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide | 1193343-79-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-(2,2-diethylhydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide
• 英文别名: 3-[[2-(2,2-diethylhydrazinyl)-3,4-dioxocyclobuten-1-yl]amino]-2-hydroxy-N,N-dimethylbenzamide
• CAS: 1193343-79-1
• 化学式: C₁₇H₂₂N₄O₄
• 分子量: 346.386
• InChiKey: OXXWFUQKMJSKBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-[(2-乙氧基-3,4-二氧代-1-环丁基-1-氨基]-2-羟基-N,N-二甲基-苄胺 、 1,1-二乙基-肼 以 乙醇 为溶剂， 反应 12.0h， 以65%的产率得到3-(2-(2,2-diethylhydrazinyl)-3,4-dioxocyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamide
  参考文献：
  名称：

  Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists

  摘要：

  We describe herein a novel series of 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective inhibitors against the CXCR2 chemokine receptor and IL-8-mediated chemotaxis of a CXCR2-expressing cell line. Furthermore, these alkyl-hydrazine series inhibitors such as 5b demonstrated acceptable metabolic stability when incubated in human and rat microsomes. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.08.014

文献信息

• [EN] NOVEL HYDRAZINO-CYCLOBUT-3-ENE-1, 2-DIONE DERIVATIVES AS CXCR2 ANTAGONISTS<br/>[FR] NOUVEAUX DÉRIVÉS D'HYDRAZINOCYCLOBUT-3-ÈNE-1,2-DIONE COMME ANTAGONISTES DE CXCR2
  申请人：MERCK SHARP & DOHME

  公开号：WO2010091543A1

  公开（公告）日：2010-08-19

  The present invention relates to novel hydrazino-cyclobut-3-ene-1,2-dione compounds of Formula (I) as selective CXCR2 antagonists, pharmaceutical compositions containing the novel compounds, as well as methods for treating or preventing chemokine mediated diseases or conditions in human and non-human animals using the novel compounds (I).

  本发明涉及一种新型的Formula (I)的肼基环丁-3-烯-1,2-二酮化合物，作为选择性CXCR2拮抗剂，含有这种新化合物的药物组合物，以及使用这种新化合物(I)治疗或预防人类和非人类动物中的趋化因子介导的疾病或症状的方法。
• [EN] CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS<br/>[FR] INHIBITEURS DU CXCR-2 PERMETTANT DE TRAITER DES TROUBLES ASSOCIÉS À UNE ARTHROPATHIE CRISTALLINE
  申请人：ARDEA BIOSCIENCES INC

  公开号：WO2017156270A1

  公开（公告）日：2017-09-14

  N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide(compound 4) are known chemokine modulators and are therefore useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of gout.

  N-(2-((2,3-二氟苄基)硫基)-6-(((2R,3S)-3,4-二羟基丁-2-基)氧基)嘧啶-4-基)氮杂环丙磺酰胺（化合物3）和N-(6-(((2R,3S)-3,4-二羟基丁-2-基)氧基)-2-((4-氟苄基)硫基)嘧啶-4-基)-3-甲基氮杂环丙磺酰胺（化合物4）是已知的化学调节剂，因此在调节趋化因子受体活性有益的疾病/症状的治疗中很有用。特别提供了用于痛风的治疗和预防的组合物和方法。
• Method for treating cancer using chemokine antagonists
  申请人：Syntrix Biosystems Inc.

  公开号：US10660909B2

  公开（公告）日：2020-05-26

  What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.

  所描述的是一种通过使用 CXCR1 和/或 CXCR2 受体拮抗剂治疗需要此类治疗的患者癌症的方法，其方法是施用治疗有效量的 CXCR1 和/或 CXCR2 拮抗剂或其药物组合物，既可单独作为单一疗法，也可与至少一种其他抗癌疗法联合使用。
• CXCR-2 inhibitors for treating crystal arthropathy disorders
  申请人：ARDEA BIOSCIENCES, INC.

  公开号：US10772886B2

  公开（公告）日：2020-09-15

  N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methyl-azetidine-1-sulfonamide (compound 4) are known chemokine modulators and are therefore useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of gout.

  N-(2-((2,3-二氟苄基)硫)-6-(((2R,3S)-3,4-二羟基丁-2-基)氧基)嘧啶-4-基)氮杂环丁烷-1-磺酰胺（化合物 3）和 N-(6-(((2R,3S)-3、6-(((2R,3S)-3,4-二羟基丁-2-基)氧基)-2-((4-氟苄基)硫基)嘧啶-4-基)-3-甲基氮杂环丁烷-1-磺酰胺（化合物 4）是已知的趋化因子调节剂，因此可用于治疗有利于调节趋化因子受体活性的疾病/病症。本文特别提供了治疗和预防痛风的组合物和方法。
• METHOD FOR TREATING CANCER USING CHEMOKINE ANTAGONISTS
  申请人：Syntrix Biosystems Inc.

  公开号：US20180177808A1

  公开（公告）日：2018-06-28

  What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.